186 related articles for article (PubMed ID: 25240613)
21. Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy.
Melli G; Taiana M; Camozzi F; Triolo D; Podini P; Quattrini A; Taroni F; Lauria G
Exp Neurol; 2008 Dec; 214(2):276-84. PubMed ID: 18809400
[TBL] [Abstract][Full Text] [Related]
22. Paclitaxel increases axonal localization and vesicular trafficking of Nav1.7.
Akin EJ; Alsaloum M; Higerd GP; Liu S; Zhao P; Dib-Hajj FB; Waxman SG; Dib-Hajj SD
Brain; 2021 Jul; 144(6):1727-1737. PubMed ID: 33734317
[TBL] [Abstract][Full Text] [Related]
23. Mitochondrial abnormality in sensory, but not motor, axons in paclitaxel-evoked painful peripheral neuropathy in the rat.
Xiao WH; Zheng H; Zheng FY; Nuydens R; Meert TF; Bennett GJ
Neuroscience; 2011 Dec; 199():461-9. PubMed ID: 22037390
[TBL] [Abstract][Full Text] [Related]
24. The protective effects of hesperidin against paclitaxel-induced peripheral neuropathy in rats.
Semis HS; Kandemir FM; Kaynar O; Dogan T; Arikan SM
Life Sci; 2021 Dec; 287():120104. PubMed ID: 34743946
[TBL] [Abstract][Full Text] [Related]
25. [Role of Transient Receptor Potential Channels in Paclitaxel- and Oxaliplatin-induced Peripheral Neuropathy].
Taguchi K
Yakugaku Zasshi; 2016; 136(2):287-96. PubMed ID: 26831807
[TBL] [Abstract][Full Text] [Related]
26. Characterisation of Immune and Neuroinflammatory Changes Associated with Chemotherapy-Induced Peripheral Neuropathy.
Makker PG; Duffy SS; Lees JG; Perera CJ; Tonkin RS; Butovsky O; Park SB; Goldstein D; Moalem-Taylor G
PLoS One; 2017; 12(1):e0170814. PubMed ID: 28125674
[TBL] [Abstract][Full Text] [Related]
27. Transient receptor potential vanilloid 4 is essential in chemotherapy-induced neuropathic pain in the rat.
Alessandri-Haber N; Dina OA; Yeh JJ; Parada CA; Reichling DB; Levine JD
J Neurosci; 2004 May; 24(18):4444-52. PubMed ID: 15128858
[TBL] [Abstract][Full Text] [Related]
28. The effects of opioid receptor antagonists on electroacupuncture-produced anti-allodynia/hyperalgesia in rats with paclitaxel-evoked peripheral neuropathy.
Meng X; Zhang Y; Li A; Xin J; Lao L; Ren K; Berman BM; Tan M; Zhang RX
Brain Res; 2011 Sep; 1414():58-65. PubMed ID: 21872220
[TBL] [Abstract][Full Text] [Related]
29. Prevention of paclitaxel-induced neuropathy through activation of the central cannabinoid type 2 receptor system.
Naguib M; Xu JJ; Diaz P; Brown DL; Cogdell D; Bie B; Hu J; Craig S; Hittelman WN
Anesth Analg; 2012 May; 114(5):1104-20. PubMed ID: 22392969
[TBL] [Abstract][Full Text] [Related]
30. Evoked and Ongoing Pain-Like Behaviours in a Rat Model of Paclitaxel-Induced Peripheral Neuropathy.
Griffiths LA; Duggett NA; Pitcher AL; Flatters SJL
Pain Res Manag; 2018; 2018():8217613. PubMed ID: 29973969
[TBL] [Abstract][Full Text] [Related]
31. The Cancer Chemotherapeutic Paclitaxel Increases Human and Rodent Sensory Neuron Responses to TRPV1 by Activation of TLR4.
Li Y; Adamek P; Zhang H; Tatsui CE; Rhines LD; Mrozkova P; Li Q; Kosturakis AK; Cassidy RM; Harrison DS; Cata JP; Sapire K; Zhang H; Kennamer-Chapman RM; Jawad AB; Ghetti A; Yan J; Palecek J; Dougherty PM
J Neurosci; 2015 Sep; 35(39):13487-500. PubMed ID: 26424893
[TBL] [Abstract][Full Text] [Related]
32. An exercise regimen prevents development paclitaxel induced peripheral neuropathy in a mouse model.
Park JS; Kim S; Hoke A
J Peripher Nerv Syst; 2015 Mar; 20(1):7-14. PubMed ID: 25858462
[TBL] [Abstract][Full Text] [Related]
33. Identification of fluocinolone acetonide to prevent paclitaxel-induced peripheral neuropathy.
Cetinkaya-Fisgin A; Joo MG; Ping X; Thakor NV; Ozturk C; Hoke A; Yang IH
J Peripher Nerv Syst; 2016 Sep; 21(3):128-33. PubMed ID: 27117347
[TBL] [Abstract][Full Text] [Related]
34. Herbal medicine Shakuyaku-kanzo-to reduces paclitaxel-induced painful peripheral neuropathy in mice.
Hidaka T; Shima T; Nagira K; Ieki M; Nakamura T; Aono Y; Kuraishi Y; Arai T; Saito S
Eur J Pain; 2009 Jan; 13(1):22-7. PubMed ID: 18472288
[TBL] [Abstract][Full Text] [Related]
35. Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery.
Rahn EJ; Deng L; Thakur GA; Vemuri K; Zvonok AM; Lai YY; Makriyannis A; Hohmann AG
Mol Pain; 2014 Apr; 10():27. PubMed ID: 24742127
[TBL] [Abstract][Full Text] [Related]
36. Modulating TRPV4 channels with paclitaxel and lithium.
Sánchez JC; Muñoz LV; Ehrlich BE
Cell Calcium; 2020 Nov; 91():102266. PubMed ID: 32871457
[TBL] [Abstract][Full Text] [Related]
37. Rikkunshito prevents paclitaxel-induced peripheral neuropathy through the suppression of the nuclear factor kappa B (NFκB) phosphorylation in spinal cord of mice.
Kamei J; Hayashi S; Sakai A; Nakanishi Y; Kai M; Ikegami M; Ikeda H
PLoS One; 2017; 12(2):e0171819. PubMed ID: 28182729
[TBL] [Abstract][Full Text] [Related]
38. Induction of monocyte chemoattractant protein-1 (MCP-1) and its receptor CCR2 in primary sensory neurons contributes to paclitaxel-induced peripheral neuropathy.
Zhang H; Boyette-Davis JA; Kosturakis AK; Li Y; Yoon SY; Walters ET; Dougherty PM
J Pain; 2013 Oct; 14(10):1031-44. PubMed ID: 23726937
[TBL] [Abstract][Full Text] [Related]
39. TRPC1 and TRPC6 channels cooperate with TRPV4 to mediate mechanical hyperalgesia and nociceptor sensitization.
Alessandri-Haber N; Dina OA; Chen X; Levine JD
J Neurosci; 2009 May; 29(19):6217-28. PubMed ID: 19439599
[TBL] [Abstract][Full Text] [Related]
40. Goshajinkigan attenuates paclitaxel-induced neuropathic pain via cortical astrocytes.
Takanashi K; Shibata K; Mizuno K; Komatsu R; Koizumi S
Pharmacol Res Perspect; 2021 Dec; 9(6):e00850. PubMed ID: 34676996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
